CBLL · CeriBell, Inc. · Stock research

Current Thesis

The August re-rating is reimbursement-driven. On 2026-08-03 CMS granted a New Technology Add-on Payment of up to $2,171 per eligible Medicare inpatient case for the Ceribell Delirium Monitor System, effective 2026-10-01. On 2026-08-10 the company raised FY2026 revenue guidance to $114–117M from $112–116M (consensus $113.979M) and disclosed a further FDA 510(k) clearance for two AI algorithms inside its existing cloud neurology portal. The narrative leg an investor is buying: a second clinical indication that gets funded before it launches, sold into the same 712 ICU accounts already running the seizure product, on 92% gross margin. Life-cycle read: ACCELERATING — dated by the 2026-08-03 NTAP, the 2026-08-10 guide raise, and target actions on 2026-08-11 and 2026-08-18.

Bullish and bearish views on CeriBell, Inc.

The model's bull view on CeriBell, Inc. (CBLL), in brief: Payment precedes launch. The NTAP (announced 2026-08-03) takes effect 2026-10-01; management has guided the commercial launch of the Delirium Monitoring Solution to Q4 2026 (2026-08-10 call). Hospitals get the economics before the rep asks for the order. Q2 2026 (reported… The bear view: The bottom line missed. Q2 EPS of $(0.51) against a $(0.47) estimate (2026-08-10). Operating expenses of $45.9M grew 37% YoY against 33% revenue growth — spend is outrunning the top line. GAAP loss $19.3M versus a $9.8M adjusted EBITDA loss in the same quarter. The $9.5M… Both cases follow in full.

Bull Case

• Payment precedes launch. The NTAP (announced 2026-08-03) takes effect 2026-10-01; management has guided the commercial launch of the Delirium Monitoring Solution to Q4 2026 (2026-08-10 call). Hospitals get the economics before the rep asks for the order.
• Q2 2026 (reported 2026-08-10): revenue $28.1M, +33% YoY; product revenue $21.2M (+33%), subscription $6.9M (+30%); 712 active accounts. Growth did not decelerate into the guide raise.
• Gross margin 92% in Q2 2026 versus 88% in Q2 2025, attributed to manufacturing efficiencies, a Vietnam production line and one-time tariff refunds. At that level, incremental revenue converts almost entirely into gross profit.
• The 2026-08-10 510(k) covers epileptiform abnormality detection and artifact reduction delivered through the existing cloud portal — software shipped into an installed base, with no new hardware sale required to monetise it.
• Guidance moved more than the beat. Q2 revenue beat by $0.812M ($28.097M vs $27.285M est.), while the FY midpoint went from $114.0M to $115.5M.
• Sell-side followed: Canaccord Genuity Buy, target to $26 on 2026-08-11; BTIG Buy, target to $30 from $28 on 2026-08-18.
• Funding is in place for the launch: $129.3M in cash and marketable securities at Q2 2026, plus a new credit facility with up to $60M of committed capital. No equity raise has been announced as of 2026-08-22.

Bear Case

• The bottom line missed. Q2 EPS of $(0.51) against a $(0.47) estimate (2026-08-10). Operating expenses of $45.9M grew 37% YoY against 33% revenue growth — spend is outrunning the top line.
• GAAP loss $19.3M versus a $9.8M adjusted EBITDA loss in the same quarter. The $9.5M difference is what the adjusted figure removes.
• The 92% gross margin includes one-time tariff refunds (management, 2026-08-10). Q3 laps a flattered number.
• NTAP sets a payment, not a purchase order. It is a per-case, time-limited Medicare add-on. Even on the guided Q4 launch, the first meaningful revenue read on delirium arrives with Q4 results in early 2027.
• Insiders sold into the move. Director Joseph M.
• The raise was narrow — $2M at the low end, $1M at the high end — relative to a 28.9% three-month move in the shares.
• Target support is thin above here. The 2026-08-21 close of $24.20 is roughly 7% under Canaccord's $26 and roughly 19% under BTIG's $30; the higher number is one house.

Setup & Price Structure

• Last completed daily close $24.20 (2026-08-21), 2.8% below the $24.89 52-week high, with a three-month price change of +28.9% and RSI(14) at 86.0.
• Insider open-market sales on 2026-08-19 printed a weighted average $25.03 — above the $24.89 52-week closing reference. INFERRED from that: the shares traded through the highest close of the window intraday and have since come back to $24.20.
• The $23.40 print of 2026-08-13 and the $25.00–$25.03 prints of 2026-08-18/19 bracket the post-earnings August range that is independently visible in filings, which is the cleanest observable structure this name offers without proprietary chart data.
• Crowding observables, stated plainly: three sell-side target actions inside eight sessions (2026-08-11 Canaccord $26, 2026-08-11 BTIG $28 reiterated, 2026-08-18 BTIG $30); executive and director supply at $23.40–$25.03; RSI(14) 86.0; no earnings date inside 30 days to force a resolution.
• Nothing in the tape argues SATURATED — coverage is a handful of houses and the delirium indication has not yet produced a revenue dollar. What argues late in this leg is the overbought reading arriving simultaneously with the end of the headline sequence.

Catalyst Calendar (next 30 days)

• 2026-08-22 → 2026-09-21: no confirmed company-dated event. September conference participation had not been announced as of 2026-08-22; the pattern is short notice (the 2026-08-12 Canaccord fireside chat was announced 2026-07-28).
• 2026-10-01 (outside the window): NTAP effective date. The first day an eligible Medicare inpatient case can carry the up-to-$2,171 add-on.
• ~2026-11-09 (est., outside the window): Q3 2026 results. Reporting cadence in 2026 has been 2026-02-24 (Q4'25), 2026-05-11 (Q1'26), 2026-08-10 (Q2'26).

Elapsed catalysts

• Q4 2026 (est., outside the window): guided commercial launch of the Delirium Monitoring Solution. No day-level date announced as of 2026-08-22. (passed 1d ago)

What Would Change Our Mind

The fundamental break is account adds stalling. 712 active accounts at Q2 2026 is the number the next print has to beat convincingly; a Q3 report that shows the account base compounding at a slower clip while FY2026 guidance of $114–117M is merely reaffirmed would mean the delirium option is being paid for with no evidence behind it yet. A Q3 gross margin below 90% would confirm that the 92% print was carried by one-time tariff refunds rather than mix.

On price, a weekly close below $21.50 would mark the August repricing as given back — that level sits under every insider sale print disclosed between 2026-08-13 and 2026-08-19 and more than 10% under the 2026-08-21 close of $24.20. Separately, if 2026-10-01 comes and goes and the Q3 call (~2026-11-09, est.) carries no delirium conversion or unit detail, the reimbursement leg becomes a 2027 story that the current multiple has to carry unaided.

The other direction matters too: a Q3 print with account adds accelerating past the Q2 pace, gross margin holding at or above 90% without tariff help, and any quantified delirium pipeline would extend the leg rather than end it.

Correlation Notes

• CBLL behaves as unprofitable high-growth medtech: 33% revenue growth with a $19.3M quarterly GAAP loss makes the shares sensitive to small-cap growth risk appetite and to rate expectations, more than to the medical-device majors.
• The shared policy factor with any NTAP-dependent device is the annual CMS IPPS rulemaking cycle, which determines whether a temporary add-on persists or lapses into base DRG payment.
• The shared demand factor with other point-of-care ICU monitoring names is hospital capital and staffing budgets, not procedure volume in elective settings.
• Despite the 2026-08-10 AI-algorithm clearance, the revenue driver is reimbursement and hospital budgets; INFERRED, the name should not be expected to track AI-infrastructure flows.
• No direct commodity linkage. Tariff exposure enters through manufacturing (the Vietnam line cited on 2026-08-10) and shows up as a gross-margin input rather than a demand variable.